Grundläggande statistik
| LEI | 549300KOGMLSPLDVHR52 |
| CIK | 1533040 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Phio Pharmaceuticals Corp.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| September 3, 2025 |
Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference Exhibit 99.1 Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-762 5th cohort patients now being treated in on-going clinical study KING OF PRUSSIA, PA-(Newsfile Corp.- September 3, 2025) — Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage bioph |
|
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 3, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commi |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 27, 2025 |
Up to 1,928,337 Shares of Common Stock S-3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-289621 PROSPECTUS Up to 1,928,337 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of up to 1,928,337 shares of common stock of Phio Pharmaceuticals Corp. (the “Company,” “we,” “us” or “our”), par value $0.0001 per share (t |
|
| August 15, 2025 |
As filed with the Securities and Exchange Commission on August 14, 2025 As filed with the Securities and Exchange Commission on August 14, 2025 Registration No. |
|
| August 15, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 Phio Pharmaceuticals Corp. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Sto |
|
| August 14, 2025 |
Form of Indemnification Agreement. Exhibit 10.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of the day of , 20 by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”) and (the “Indemnitee”). RECITALS A. The Company’s board of directors (the “Board”) has determined that the increasing difficulty in attracting and retaining qualified persons as directors and officer |
|
| August 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36304 Phi |
|
| August 14, 2025 |
Exhibit 10.3 SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This SEPARATION AND GENERAL RELEASE OF CLAIMS (this "Agreement") is entered into by and between Robert Infarinato ("Employee") and Phio Pharmaceuticals Corp., a Delaware corporation (the "Company"). Employee and the Company are each referred to herein as a "£fil1Y" and collectively as the "Parties." WHEREAS, Employee's employment with |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commiss |
|
| August 14, 2025 |
Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 5th cohort enrolling patients in on-going clinical study KING OF PRUSSIA, PA-(Newsfile Corp.-August 14, 2025) — Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company developing therape |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissio |
|
| July 30, 2025 |
Form of Series J/K Warrant, dated July 28, 2025. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 30, 2025 |
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds Exhibit 99.1 Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds King of Prussia, Pennsylvania-(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today announced the entry into |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| July 30, 2025 |
Exhibit 10.1 PHIO PHARMACEUTICALS CORP. July 25, 2025 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Phio Pharmaceuticals Corp. (the “Company”) is pleased to offer to you the opportunity to exercise, in cash, all of the warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), |
|
| July 30, 2025 |
Form of Placement Agent Warrant, dated July 28, 2025. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 25, 2025 |
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance Exhibit 99.1 Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance -Agreement covers contract development and manufacturing of lead compound PH-762 King of Prussia, Pennsylvania-(Newsfile Corp.-July 25, 2025) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gen |
|
| July 25, 2025 |
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort Exhibit 99.2 Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patient King of Prussia — (Newsfile Corp.-July 25, 2025) -Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage siRNA biopharmaceutical company developing th |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissio |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 7, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissio |
|
| June 26, 2025 |
Exhibit 99.1 Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL® PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort -Phio’s lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohort Marlborough, Massachusetts-(Newsfile Corp.-June 25, 2025) — Phio |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 6, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| June 12, 2025 |
Exhibit 99.1 Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL ® siRNA Portfolio – Robert Infarinato named VP, Strategic Development – Lisa Carson named as new VP, Finance and Administration Marlborough, Massachusetts—(Newsfile Corp.-June 6, 2025) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage siRNA biopharmaceutical company devel |
|
| June 12, 2025 |
Offer Letter, executed April 21, 2025 by and between the Company and Lisa Carson Exhibit 10.1 04/18/2025 Lisa Carson Dear Lisa, I am pleased to offer you the position of Vice President Finance and Administration with Phio Pharmaceuticals Corp. (the “Company”) reporting to the Chairman, President and Chief Executive Officer, effective May 12, 2025 (the “Effective Date”). You will receive a base salary of $290,000 annually, payable every two weeks in accordance with the regular |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 15, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| May 15, 2025 |
Exhibit 99.1 Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical study Marlborough, Massachusetts-(Newsfile Corp.-May 15, 2025) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company de |
|
| May 15, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36304 Ph |
|
| May 7, 2025 |
Exhibit 99.1 Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL® PH-762 Skin Cancer Clinical Trial – Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort – Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Ann |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 7, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 17, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissi |
|
| April 22, 2025 |
Letter of BDO USA P.C., dated April 21, 2025 Exhibit 16.1 April 21, 2025 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on April 17, 2025, to be filed by our former client, Phio Pharmaceuticals Corp. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, |
|
| April 9, 2025 |
Exhibit 99.1 Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL® PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort -Phio’s lead clinical siRNA compound PH-762 demonstrates supportive safety profile in third cohort, permitting escalation in next dose concentration Marlborough, Massachusetts-(Newsfile Corp.-April 9, 2025) — Phio Pharmaceutic |
|
| April 9, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 9, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissio |
|
| March 31, 2025 |
Exhibit 99.1 Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762 3rd Cohort now fully enrolled in on-going clinical study Marlborough, Massachusetts-(Newsfile Corp.-March 31, 2025) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company developing |
|
| March 31, 2025 |
Exhibit 19.1 PHIO PHARMACEUTICALS CORP. Insider Trading Policy Purpose This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of Phio Pharmaceuticals Corp. (the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Company’s Board of Directors has adopted this Poli |
|
| March 31, 2025 |
Exhibit 10.30 FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF ROBERT J. BITTERMAN This First Amendment to the Employment Agreement of Robert J. Bitterman (the “Amendment”) is entered into this 25th day of March, 2025, by and between Robert J. Bitterman (“Executive”) and Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”). Recitals WHEREAS, the Company and Executive have entered into |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 31, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissi |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-363 |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 19, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commi |
|
| February 20, 2025 |
Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors Exhibit 99.1 Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors MARLBOROUGH, Mass., February 20, 2025 (NEWSFILE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body’s immune cells more effective in killing cancer cells. Phio anno |
|
| January 29, 2025 |
Up to 5,930,016 Shares of Common Stock Prospectus Filed Pursuant to Rule 424(b)(3) Registration No. 333-284381 Up to 5,930,016 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of up to 5,930,016 shares of common stock of Phio Pharmaceuticals Corp. (the “Company,” “we,” “us” or “our”), par value $0.0001 per share (the “ |
|
| January 27, 2025 |
PHIO PHARMACEUTICALS CORP. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, MA 01752 PHIO PHARMACEUTICALS CORP. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, MA 01752 January 27, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika Sheppard Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed January 21, 2025 File No. 333-284381 Request for Acceler |
|
| January 21, 2025 |
As filed with the Securities and Exchange Commission on January 21, 2025 Table of Contents As filed with the Securities and Exchange Commission on January 21, 2025 Registration No. |
|
| January 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Phio Pharmaceuticals Corp. |
|
| January 17, 2025 |
Form of Series I Common Stock Warrant. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 17, 2025 |
Phio Pharmaceuticals Corp. 610,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-279557 PROSPECTUS SUPPLEMENT (To Prospectus dated July 1, 2024) Phio Pharmaceuticals Corp. 610,000 Shares of Common Stock We are offering 610,000 shares of our common stock, par value $0.0001 per share (“Common Stock”) to several institutional investors pursuant to this prospectus supplement and the accompanying prospectus. In a concu |
|
| January 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 16, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commis |
|
| January 17, 2025 |
Form of Placement Agent Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 17, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 16, 2025, by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms an |
|
| January 17, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| January 17, 2025 |
Exhibit 99.1 Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MARLBOROUGH, Mass., January 16, 2025 (NEWSFILE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body’s immune cells more effective in killing cancer |
|
| January 15, 2025 |
Phio Pharmaceuticals Corp. 833,335 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-279557 PROSPECTUS SUPPLEMENT (To Prospectus dated July 1, 2024) Phio Pharmaceuticals Corp. 833,335 Shares of Common Stock We are offering 833,335 shares of our common stock, par value $0.0001 per share (“Common Stock”) to several institutional investors pursuant to this prospectus supplement and the accompanying prospectus. In a concu |
|
| January 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 14, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commis |
|
| January 15, 2025 |
Exhibit 99.1 Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MARLBOROUGH, Mass., January 15, 2025 (NEWSFILE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body’s immune cells more effective in killing cancer c |
|
| January 15, 2025 |
Form of Placement Agent Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 15, 2025 |
Form of Series H Common Stock Warrant. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 15, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 14, 2025, by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms an |
|
| January 14, 2025 |
Exhibit 99.1 Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MARLBOROUGH, Mass., January 14, 2025 (NEWSFILE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body’s immune cells more effective in killing cancer |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 13, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commis |
|
| January 14, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 13, 2025, by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms an |
|
| January 14, 2025 |
Phio Pharmaceuticals Corp. 1,063,670 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-279557 PROSPECTUS SUPPLEMENT (To Prospectus dated July 1, 2024) Phio Pharmaceuticals Corp. 1,063,670 Shares of Common Stock We are offering 1,063,670 shares of our common stock, par value $0.0001 per share (“Common Stock”) to several institutional investors pursuant to this prospectus supplement and the accompanying prospectus. In a c |
|
| January 14, 2025 |
Form of Series G Common Stock Warrant. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 14, 2025 |
Form of Placement Agent Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 13, 2025 |
Exhibit 99.1 Phio Pharmaceuticals Announces Promising Results of Second Cohort from its Ongoing Clinical Study of PH-762 Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma MARLBOROUGH, Mass., Jan 13, 2025 (NEWSFILE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 13, 2025 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commis |
|
| December 27, 2024 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| December 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 23, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commi |
|
| December 26, 2024 |
EXHIBIT II JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the shares of common stock of Phio Pharmaceuticals Corp. |
|
| December 26, 2024 |
Exhibit I LIMITED POWER OF ATTORNEY THIS LIMITED POWER OF ATTORNEY given on the 16th day of July, 2015 by CVI Investments, Inc. |
|
| December 26, 2024 |
Form of Placement Agent Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 26, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 23, 2024, by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms a |
|
| December 26, 2024 |
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MARLBOROUGH, Mass., Dec 23, 2024 (NEWSFILE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body’s immune cells more effective in killing cancer cells, today annou |
|
| December 26, 2024 |
Form of Series F Common Stock Warrant. EX-4.1 2 phioex0401.htm FORM OF SERIES F COMMON STOCK WARRANT, DATED DECEMBER 24, 2024 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT” |
|
| December 23, 2024 |
Phio Pharmaceuticals Corp. 240,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-279557 PROSPECTUS SUPPLEMENT (To Prospectus dated July 1, 2024) Phio Pharmaceuticals Corp. 240,000 Shares of Common Stock We are offering 240,000 shares of our common stock, par value $0.0001 per share (“Common Stock”) to several institutional investors pursuant to this prospectus supplement and the accompanying prospectus. In a concu |
|
| December 20, 2024 |
Phio Pharmaceuticals Corp. 437,192 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-279557 PROSPECTUS SUPPLEMENT (To Prospectus dated July 1, 2024) Phio Pharmaceuticals Corp. 437,192 Shares of Common Stock We are offering 437,192 shares of our common stock, par value $0.0001 per share (“Common Stock”) to several institutional investors pursuant to this prospectus supplement and the accompanying prospectus. In a concu |
|
| December 20, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 19, 2024, by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms a |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 19, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commi |
|
| December 20, 2024 |
Form of Placement Agent Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 20, 2024 |
Form of Series E Common Stock Warrant. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 20, 2024 |
Exhibit 99.1 Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MARLBOROUGH, Mass., Dec 19, 2024 (NEWSFILE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body’s immune cells more effective in killing cancer cell |
|
| December 19, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 18, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commi |
|
| December 19, 2024 |
Exhibit 99.1 . Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to continue to Third Dose Cohort in its Clinical Study of PH-762 -Phio’s Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentration MARLBOROUGH, Mass., Dec 19, 2024 (NEWSFILE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) i |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 14, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commi |
|
| November 14, 2024 |
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update . Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update MARLBOROUGH, Mass., November 14, 2024 (NEWSFILE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company exploring new pathways towards a cancer-free future by using its INTASYL® siRNA gene silencing technology designed to make the body’s immune cells more effective in kil |
|
| November 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3630 |
|
| November 13, 2024 |
SC 13G/A 1 ea022071808-13ga5intraphio.htm AMENDMENT NO. 5 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Phio Pharmaceuticals Corp. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 71880W501 (CUSIP Number) September 30, 2024 (Date of Event Whic |
|
| November 7, 2024 |
Exhibit 99.1 Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Presenting new clinical data from Phio’s on-going Phase 1b trial MARLBOROUGH, Mass., Nov 7, 2024 (NEWSFILE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its |
|
| November 7, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 7, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commis |
|
| August 14, 2024 |
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update MARLBOROUGH, Mass., August 14, 2024—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for t |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 14, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commiss |
|
| August 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36304 Phi |
|
| August 5, 2024 |
Up to 1,131,468 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No 333-281052 Prospectus Up to 1,131,468 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of up to 1,131,468 shares of common stock of Phio Pharmaceuticals Corp. |
|
| August 1, 2024 |
Employment Agreement, dated July 9, 2024, by and between the Company and Robert M. Infarinato. Exhibit 10.1 07/09/2024 Robert M. Infarinato Dear Bob, I am pleased to offer you the position of Vice President, Chief Financial Officer with Phio Pharmaceuticals Corp. (the “Company”) reporting to the Chairman, President and Chief Executive Officer, effective August 1, 2024 (the "Effective Date"). You will receive a base salary of $180,000 annually, payable every two weeks in accordance with the |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 15, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissio |
|
| August 1, 2024 |
Phio Pharmaceuticals Announces New Chief Financial Officer Exhibit 99.1 Phio Pharmaceuticals Announces New Chief Financial Officer MARLBOROUGH, Massachusetts – (Newsfile Corp. – August 1, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced the appointment of Robert M. Infar |
|
| July 30, 2024 |
PHIO PHARMACEUTICALS CORP. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, MA 01752 PHIO PHARMACEUTICALS CORP. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, MA 01752 July 30, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed July 26, 2024 File No. 333-281052 Request for Acceleration o |
|
| July 26, 2024 |
As filed with the Securities and Exchange Commission on July 26, 2024 Table of Contents As filed with the Securities and Exchange Commission on July 26, 2024 Registration No. |
|
| July 26, 2024 |
Exhibit 107 Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Phio Pharmaceuticals Corp. |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 19, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissio |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 11, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissio |
|
| July 12, 2024 |
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds Exhibit 99.1 Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds MARLBOROUGH, Massachusetts – (Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the “Company”), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today anno |
|
| July 12, 2024 |
Exhibit 10.1 PHIO PHARMACEUTICALS CORP. July 11, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Phio Pharmaceuticals Corp. (the “Company”) is pleased to offer to you the opportunity to exercise all of the warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and set for |
|
| July 12, 2024 |
Form of Placement Agent Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 12, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 3, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| July 5, 2024 |
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds Exhibit 99.1 Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds MARLBOROUGH, Massachusetts-(Newsfile Corp. – July 5, 2024)—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its sh |
|
| July 2, 2024 |
Phio Pharmaceuticals Announces Reverse Stock Split Exhibit 99.1 Phio Pharmaceuticals Announces Reverse Stock Split MARLBOROUGH, Mass. (Newsfile Corp. – July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the “Company”), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company’s Board of Directors |
|
| July 2, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PHIO PHARMACEUTICALS CORP. Phio Pharmaceuticals Corp. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”), hereby certifies as follows: FIRST: That the Board of Directors of the Corporation ha |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 1, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| June 27, 2024 |
PHIO PHARMACEUTICALS CORP. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, MA 01752 PHIO PHARMACEUTICALS CORP. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, MA 01752 June 27, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Tamika Sheppard Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-3 Filed May 20, 2024 File No. 333-279557 Request for Acceleration o |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 17, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissio |
|
| June 21, 2024 |
2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan, as amended and restated. Exhibit 10.1 PHIO PHARMACEUTICALS CORP. 2020 LONG TERM INCENTIVE PLAN 1. GENERAL. (a) Successor to Prior Plan. This Plan is the successor to the Phio Pharmaceuticals Corp. 2012 Long Term Incentive Plan, as amended (the “Prior Plan”). From and after 12:01 a.m. Eastern time on the Effective Date, no additional stock awards will be granted under the Prior Plan. (b) Eligible Award Recipients. Employee |
|
| May 28, 2024 |
Exhibit 99.1 Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio’s Lead Compound PH-762 -Intratumoral PH-762 has encouraging safety profile in the initial cohort - Escalation to proceed to next dose concentration MARLBOROUGH, Mass., May 28, 2024 (NEWSFILE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biot |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 28, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| May 20, 2024 |
As filed with the Securities and Exchange Commission on May 20, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 20, 2024 Registration No. |
|
| May 20, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Phio Pharmaceuticals Corp. |
|
| May 20, 2024 |
PHIO PHARMACEUTICALS CORP. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, MA 01752 PHIO PHARMACEUTICALS CORP. 11 Apex Drive, Suite 300A, PMB 2006 Marlborough, MA 01752 May 20, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Phio Pharmaceuticals Corp. Request to Withdraw Registration Statement on Form S-1 Filed May 17, 2024 File No. 333-279511 Ladies and Gentlemen: Pursuan |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| May 17, 2024 |
As filed with the Securities and Exchange Commission on May 17, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 17, 2024 Registration No. |
|
| May 17, 2024 |
Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (the “Agreement”), dated as of May 16, 2024, by and between PHIO PHARMACEUTICALS CORP., a Delaware corporation (the “Company”), and TRITON FUNDS LP, a Delaware limited partnership (the “Investor”). RECITALS WHEREAS, subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes |
|
| May 17, 2024 |
Phio Pharmaceuticals Secures New Investor --Fund invests in microcap equities Exhibit 99.1 Phio Pharmaceuticals Secures New Investor -Fund invests in microcap equities MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has entered into a purchas |
|
| May 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Phio Pharmaceuticals Corp. |
|
| May 17, 2024 |
Phio Pharmaceuticals Corp. 862,500 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-256100 PROSPECTUS SUPPLEMENT (To Prospectus dated May 21, 2021) Phio Pharmaceuticals Corp. 862,500 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to 862,500 shares of our common stock, par value $0.0001 per share (“Common Stock”) to Triton Funds LP (“Triton”) pursuant to a purchase agreement e |
|
| May 9, 2024 |
Exhibit 99.1 Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update –Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 –Three patients have been enrolled MARLBOROUGH, Mass., May 9, 2024 (GLOBE NEWSWIRE)—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene sil |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 9, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36304 Ph |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 2, 2024 |
Exhibit 99.1 Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update –Four sites across the country participating in clinical trial for lead product candidate PH-762 –Two patients have already completed treatment – New patent granted for skin related treatments, extending Phio’s expertise in dermatological treatments for skin care and skin cancer MARLBOROUGH, Mass |
|
| April 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 2, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissio |
|
| April 1, 2024 |
Exhibit 4.16 to our Annual Report on Form 10-K for the year ended December 31, 2023 Exhibit 4.16 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of our common stock and a summary of our preferred stock. You should refer to our Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) and our Amended and Restated Bylaws (the “Bylaws”), each of which are i |
|
| April 1, 2024 |
Phio Pharmaceuticals Corp. Incentive Compensation Recovery Policy. Exhibit 97.1 Phio Pharmaceuticals Corp. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Phio Pharmaceuticals Corp. (the “Company”) on September 27, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the best |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-363 |
|
| February 6, 2024 |
SC 13G/A 1 ea192888-13ga4intraphio.htm AMENDMENT NO. 4 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Phio Pharmaceuticals Corp. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 71880W402 (CUSIP Number) December 31, 2023 (Date of Event Which Re |
|
| January 26, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 24, 2024 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commis |
|
| December 28, 2023 |
Up to 4,420,273 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-276146 Prospectus Up to 4,420,273 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of up to 4,420,273 shares of common stock of Phio Pharmaceuticals Corp. (the “Company,” “we,” “us” or “our”), par value $0.000 |
|
| December 22, 2023 |
PHIO PHARMACEUTICALS CORP. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 PHIO PHARMACEUTICALS CORP. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 December 22, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed December 19, 2023 File No. 333-276146 Request for Acceleratio |
|
| December 19, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Phio Pharmaceuticals Corp. |
|
| December 19, 2023 |
As filed with the Securities and Exchange Commission on December 19, 2023 Table of Contents As filed with the Securities and Exchange Commission on December 19, 2023 Registration No. |
|
| December 8, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 8, 2023 |
Form of Placement Agent Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 8, 2023 |
Exhibit 10.1 PHIO PHARMACEUTICALS CORP. December 6, 2023 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Phio Pharmaceuticals Corp. (the “Company”) is pleased to offer to you the opportunity to exercise all of the warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and set |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 6, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commis |
|
| December 8, 2023 |
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds Exhibit 99.1 Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds MARLBOROUGH, Mass., December 7, 2023 (GLOBE NEWSWIRE)—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced the agreement by several ac |
|
| November 9, 2023 |
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update MARLBOROUGH, Mass., November 9, 2023 (GLOBE NEWSWIRE)—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial res |
|
| November 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3630 |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 9, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commis |
|
| November 9, 2023 |
Exhibit 99.2 Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas MARLBOROUGH, Mass., November 9, 2023 (GLOBE NEWSWIRE)—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more e |
|
| November 9, 2023 |
Phio Pharmaceuticals Corp. 2020 Long Term Incentive Plan, as amended and restated. Exhibit 10.1 PHIO PHARMACEUTICALS CORP. 2020 LONG TERM INCENTIVE PLAN 1. GENERAL. (a) Successor to Prior Plan. This Plan is the successor to the Phio Pharmaceuticals Corp. 2012 Long Term Incentive Plan, as amended (the “Prior Plan”). From and after 12:01 a.m. Eastern time on the Effective Date, no additional stock awards will be granted under the Prior Plan. (b) Eligible Award Recipients. Employee |
|
| November 9, 2023 |
Form of Nonqualified Stock Option Award under the Company’s 2020 Long Term Incentive Plan. Exhibit 10.2 Terms of Nonqualified Stock Option Award Type: Non-Statutory Stock Award Name: [Name] (the “Participant”) Number of Shares of Stock subject to Award: [Number] Price per Share: $[Exercise price no less than FMV] Grant Date [Date] (“Grant Date”) Vesting Commencement Date: [Date] Vesting Schedule: [Description of vesting schedule] Expiration Date: [Date 10 years following the date of gra |
|
| September 29, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Phio Pharmaceuticals Corp. |
|
| September 29, 2023 |
As filed with the Securities and Exchange Commission on September 29, 2023 As filed with the Securities and Exchange Commission on September 29, 2023 Registration No. |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 21, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commiss |
|
| August 21, 2023 |
Exhibit 99.1 Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute Trial targeting treatment of metastatic melanoma and other solid tumors MARLBOROUGH, MA., August 21, 2023 (Globe Newswire) —Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform tec |
|
| August 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 10, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commiss |
|
| August 10, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36304 Phi |
|
| August 10, 2023 |
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update MARLBOROUGH, Mass., August 10, 2023—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quar |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 20, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissio |
|
| July 26, 2023 |
2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan, as amended and restated. Exhibit 10.1 PHIO PHARMACEUTICALS CORP. 2020 LONG TERM INCENTIVE PLAN 1. GENERAL. (a) Successor to Prior Plan. This Plan is the successor to the Phio Pharmaceuticals Corp. 2012 Long Term Incentive Plan, as amended (the “Prior Plan”). From and after 12:01 a.m. Eastern time on the Effective Date, no additional stock awards will be granted under the Prior Plan. (b) Eligible Award Recipients. Employee |
|
| June 20, 2023 |
Up to 2,640,191 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-272526 Up to 2,640,191 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of up to 2,640,191 shares of common stock of Phio Pharmaceuticals Corp. (the “Company,” “we,” “us” or “our”), par value $0.0001 per share |
|
| June 14, 2023 |
PHIO PHARMACEUTICALS CORP. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 PHIO PHARMACEUTICALS CORP. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 June 14, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed June 8, 2023 File No. 333-272526 Request for Acceleration of Effectiv |
|
| June 9, 2023 |
DEFA14A 1 phiodefa14a.htm PROXY CARD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| June 8, 2023 |
As filed with the Securities and Exchange Commission on June 8, 2023 Table of Contents As filed with the Securities and Exchange Commission on June 8, 2023 Registration No. |
|
| June 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Phio Pharmaceuticals Corp. |
|
| June 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 31, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| June 2, 2023 |
Form of Series A Common Stock Warrant. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 2, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 31, 2023, by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| June 2, 2023 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 31, 2023, by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and co |
|
| June 2, 2023 |
Exhibit 99.1 Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules MARLBOROUGH, Mass., May 31, 2023 /PRNewswire/ - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumo |
|
| June 2, 2023 |
Form of Series B Common Stock Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 2, 2023 |
Exhibit 99.2 Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules Marlborough, Mass., June 2, 2023 /PRNewswire/ - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in k |
|
| June 2, 2023 |
Form of Pre-funded Common Stock Warrant, dated June 2, 2023. Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 2, 2023 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 31, 2023, by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities |
|
| June 1, 2023 |
Phio Pharmaceuticals Corp. 233,646 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-256100 PROSPECTUS SUPPLEMENT (To Prospectus dated May 21, 2021) Phio Pharmaceuticals Corp. 233,646 Shares of Common Stock We are offering 233,646 shares of our common stock, par value $0.0001 per share (“Common Stock”) to several institutional investors pursuant to this prospectus supplement and the accompanying pros |
|
| May 24, 2023 |
Exhibit 99.1 Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx’s Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute One of two newly announced clinical trials for its lead product candidate, PH-762 MARLBOROUGH, MA., May 24, 2023 /PRNewswire—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 24, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2023 |
Exhibit 99.1 Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas MARLBOROUGH, Mass., May 16, 2023 /PRNewswire—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2023 |
Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update Exhibit 99.1 Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update MARLBOROUGH, Mass., May 11, 2023 /PRNewswire—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for |
|
| May 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36304 Ph |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 11, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2023 |
Up to 734,515 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-271521 Prospectus Up to 734,515 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of up to 734,515 shares of common stock, par value $0.0001 per share (the “Common Stock) consisting of (a) up to 353,983 shares |
|
| May 5, 2023 |
PHIO PHARMACEUTICALS CORP. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 PHIO PHARMACEUTICALS CORP. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 May 5, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed April 28, 2023 File No. 333-271521 Request for Acceleration of Ef |
|
| April 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Phio Pharmaceuticals Corp. |
|
| April 28, 2023 |
As filed with the Securities and Exchange Commission on April 28, 2023 Table of Contents As filed with the Securities and Exchange Commission on April 28, 2023 Registration No. |
|
| April 20, 2023 |
Form of Series B Common Stock Warrant. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 20, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-238204 PROSPECTUS SUPPLEMENT (To Prospectus dated June 1, 2020) Phio Pharmaceuticals Corp. 17,845 Shares of Common Stock Issuable upon Exercise of Outstanding Warrants This prospectus supplement modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, our prospectus (the “Original |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 18, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissi |
|
| April 20, 2023 |
Exhibit 99.2 Phio Pharmaceuticals Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Marlborough, Mass., April 20, 2023 /PRNewswire/ - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today annou |
|
| April 20, 2023 |
Form of Existing Warrant Amendment. Exhibit 4.3 April 18, 2023 Holder of Warrants to Purchase Common Stock issued in [], [] and [] Re: Amendment to Existing Warrant Dear Holder: Reference is hereby made to the concurrent registered offering on or about the date hereof (the “Offering”) by Phio Pharmaceuticals Corp. (the “Company”) of its securities (collectively, the “Securities”). This letter confirms that, in consideration for (i) |
|
| April 20, 2023 |
424B3 1 phio424b3-17318.htm FORM 424(B)(3) Filed Pursuant to Rule 424(b)(3) Registration Nos. 333-227173 and 333-227617 PROSPECTUS SUPPLEMENT (To Prospectus dated October 1, 2018) Phio Pharmaceuticals Corp. 17,318 Shares of Common Stock Issuable upon Exercise of Outstanding Warrants This prospectus supplement modifies, supersedes and supplements certain information contained in, and should be read |
|
| April 20, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-234032 PROSPECTUS SUPPLEMENT (To Prospectus dated February 11, 2020) Phio Pharmaceuticals Corp. 42,188 Shares of Common Stock Issuable upon Exercise of Outstanding Warrants This prospectus supplement modifies, supersedes and supplements certain information contained in, and should be read in conjunction with our prospectus (the “Origi |
|
| April 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 20, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissi |
|
| April 20, 2023 |
Form of Series A Common Stock Warrant. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 20, 2023 |
Phio Pharmaceuticals Corp. 772 Shares of Common Stock Issuable upon Exercise of Outstanding Warrants Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-224799 PROSPECTUS SUPPLEMENT (To Prospectus dated May 31, 2018) Phio Pharmaceuticals Corp. 772 Shares of Common Stock Issuable upon Exercise of Outstanding Warrants This prospectus supplement modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, our prospectus (the “Original Pro |
|
| April 20, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-252588 PROSPECTUS SUPPLEMENT (To Prospectus dated February 8, 2021) Phio Pharmaceuticals Corp. 101,792 Shares of Common Stock Issuable upon Exercise of Outstanding Warrants This prospectus supplement modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, our prospectus (the “Orig |
|
| April 20, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 18, 2023, by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and |
|
| April 20, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-239779 PROSPECTUS SUPPLEMENT (To Prospectus dated July 17, 2020) Phio Pharmaceuticals Corp. 11,704 Shares of Common Stock Issuable upon Exercise of Outstanding Warrants This prospectus supplement modifies, supersedes and supplements certain information contained in, and should be read in conjunction with, our prospectus (the “Original |
|
| April 20, 2023 |
Exhibit 99.1 Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Marlborough, Mass., April 18, 2023 /PRNewswire/ - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that i |
|
| April 19, 2023 |
Phio Pharmaceuticals Corp. 353,983 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-256100 PROSPECTUS SUPPLEMENT (To Prospectus dated May 21, 2021) Phio Pharmaceuticals Corp. 353,983 Shares of Common Stock We are offering 353,983 shares of our common stock, par value $0.0001 per share (“Common Stock”) to several institutional investors pursuant to this prospectus supplement and the accompanying prospectus. In a concu |
|
| April 18, 2023 |
EX-99.1 2 phioex9901.htm PRESS RELEASE Exhibit 99.1 Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL - Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 - MARLBOROUGH, Mass., April 18, 2023 /PRNewswire—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage b |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 18, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissi |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 17, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissi |
|
| April 17, 2023 |
Exhibit 99.1 Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity - Data to be presented at American Association for Cancer Research (AACR) Annual Meeting 2023 - MARLBOROUGH, Mass., April 17, 2023 /PRNewswire—Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi pla |
|
| March 22, 2023 |
Exhibit 99.1 Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update – Following safety data review by the DMC, enrollment is now open for the second cohort of its Phase 1b study of PH-762 for the treatment of advanced melanoma – – Received confirmation from the FDA that the planned Phase 1 clinical trial in patients with advanced solid tumors, in collaboration wi |
|
| March 22, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-363 |
|
| March 22, 2023 |
Exhibit 10.11 SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (this “Agreement”) is entered into by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”) and Gerrit D. Dispersyn, Dr. Med. Sc. (the “Executive”) (each of the foregoing individually a “Party” and collectively the “Parties”). WHEREAS, Executive’s employ |
|
| March 22, 2023 |
EX-10.2 2 phioex1002.htm CLINICAL CO-DEVELOPMENT AGREEMENT Exhibit 10.2 *** Certain identified information has been excluded from this exhibit because it is both not material and the type the registrant treats as private or confidential CLINICAL CO-DEVELOPMENT AGREEMENT This Clinical Co-Development Agreement (“Agreement”), entered into as of February 26, 2021 (the “Effective Date”), is by and betw |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 22, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissi |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 10, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commissi |
|
| February 22, 2023 |
Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer Exhibit 99.1 Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer MARLBOROUGH, Mass., Feb. 22, 2023 / PRNewswire / - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that Robert Bitterman has |
|
| February 22, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This AGREEMENT (the “Agreement”), entered into as of February 20th 2023 (the “Commencement Date”), by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), and Robert J. Bitterman, (the “Executive”). W I T N E S S E T H: WHEREAS, the Executive has been serving as the Interim Executive Chairman and Interim Principal Executive Officer since |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 17, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation) (Commi |
|
| February 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 9, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or organ |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Phio Pharmaceuticals Corp. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 71880W303 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 24, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or organ |
|
| January 25, 2023 |
Phio Pharmaceuticals Announces Reverse Stock Split Exhibit 99.1 Phio Pharmaceuticals Announces Reverse Stock Split MARLBOROUGH, Mass., January 25, 2023 /PRNewswire/ - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the Company’s Board of Directors has approved a reverse s |
|
| January 25, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PHIO PHARMACEUTICALS CORP. Phio Pharmaceuticals Corp. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”), hereby certifies as follows: FIRST: That the Board of Directors of the Corporation ha |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 4, 2023 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or organi |
|
| January 6, 2023 |
Exhibit 99.1 1 www.phiopharma.com I Ticker: PHIO (NASDAQ) Phio Pharmaceuticals Proprietary Innovations in Immuno - oncology (I/O) Therapeutic Applications 2 This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Words such as ?believes,? ?anticipates,? ?plans,? ?expects,? ?indicates,? ?will,? ?intends,? ?potential,? ?sug |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 21, 2022 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or orga |
|
| December 21, 2022 |
Exhibit 99.1 Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma Marlborough, Mass., December 21, 2022/PR Newswire/- Phio Pharmaceuticals Corp., today announced it expects to file an IND in the US in the first half of 2023 for a Phase 1b clinical trial of its INTASYL? compound, PH-762. Phio is a clinical stage biotechnology com |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 16, 2022 |
Certificate of Designation of Series D Preferred Stock, dated November 16, 2022. Exhibit 3.1 PHIO PHARMACEUTICALS CORP. CERTIFICATE OF DESIGNATION OF SERIES D PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Phio Pharmaceuticals Corp., a Delaware corporation (the “Corporation”), that the following resolution was duly adopted by the board of directors of the Corporation (the “Board |
|
| November 16, 2022 |
Exhibit 10.1 Phio Pharmaceuticals Corp. Series D Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENT THIS AGREEMENT, dated as of November 16, 2022, is by and between Phio Pharmaceuticals Corp., a Delaware corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good, valuable and adequate co |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 16, 2022 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or orga |
|
| November 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3630 |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 10, 2022 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or orga |
|
| November 10, 2022 |
Exhibit 99.1 Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update New executive team leading development of Phio?s RNAi compounds and proprietary INTASYL? platform Continuing enrollment in its Phase 1b study of PH-762 for the treatment of advanced melanoma Additional studies demonstrate INTASYL?s activity against multiple |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 26, 2022 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or org |
|
| September 29, 2022 |
Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman Exhibit 99.1 Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman MARLBOROUGH, Mass., Sept. 29, 2022 /PRNewswire/ - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL?) therapeutic platform, today announced the appointment of Robert Bi |
|
| August 26, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 25, 2022 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or organi |
|
| August 12, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 9, 2022 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or organiz |
|
| August 11, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36304 Phi |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 11, 2022 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or organi |
|
| August 11, 2022 |
Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Initiated dosing of subjects and enrollment ongoing in the first-in-human clinical study of PH-762 for the treatment of advanced melanoma; expect to announce top-line data from the first group of subjects in Q1 2023 Expects to initiate a clinical trial evaluating the use of PH-762 and ?doub |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 12, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36304 Ph |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 12, 2022 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or organizat |
|
| May 12, 2022 |
Exhibit 99.1 Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in the second half of 2022 Marlborough, Mass., March 12, 2022/PRNewswire/ - Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotec |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 4, 2022 PHIO PHARMACEUTICALS CORP. (Exact name of registrant as specified in its charter) Delaware 001-36304 45-3215903 (State or other jurisdiction of incorporation or organizati |
|
| May 2, 2022 |
Amended and Restated Bylaws of Phio Pharmaceuticals Corp. Exhibit 3.1 PHIO PHARMACEUTICALS CORP. (the ?Corporation?) SIXTH AMENDED & RESTATED BYLAWS SECTION 1?STOCKHOLDERS Section 1.1. Annual Meeting. An annual meeting of the stockholders for the election of directors to succeed those whose term expire and for the transaction of such other business as may properly come before the meeting shall be held at the place, if any, within or without the State of |
